Aura Biosciences (Aura Biosciences) EV-to-Revenue : (As of Jun. 02, 2024)

View and export this data going back to 2021. Start your Free Trial

What is Aura Biosciences EV-to-Revenue?

EV-to-Revenue is calculated as enterprise value divided by its revenue. As of today, Aura Biosciences's enterprise value is $180.59 Mil. Aura Biosciences's Revenue for the trailing twelve months (TTM) ended in Mar. 2024 was $0.00 Mil. Therefore, Aura Biosciences's EV-to-Revenue for today is .

The historical rank and industry rank for Aura Biosciences's EV-to-Revenue or its related term are showing as below:

AURA's EV-to-Revenue is not ranked ^*
in the Biotechnology industry.
Industry Median: 8.1
* Ranked among companies with meaningful EV-to-Revenue only.

The reason Enterprise Value is used is because Enterprise Value is more real in reflecting how much an investor pays when buying a company. For detais, go to Enterprise Value.

EV-to-Revenue is a similar ratio to PS Ratio, except here Enterprise Value instead of Market Cap is used in the calculation.

As of today (2024-06-02), Aura Biosciences's stock price is $7.35. Aura Biosciences's Revenue per Share for the trailing twelve months (TTM) ended in Mar. 2024 was $0.00. Therefore, Aura Biosciences's PS Ratio for today is .

Aura Biosciences EV-to-Revenue Historical Data

The historical data trend for Aura Biosciences's EV-to-Revenue can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Aura Biosciences EV-to-Revenue Chart

Aura Biosciences Annual Data

Trend

Dec19

Dec20

Dec21

Dec22

Dec23

EV-to-Revenue

Aura Biosciences Quarterly Data
	Dec19	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24
EV-to-Revenue	Get a 7-Day Free Trial												-	-	-	-	-

Competitive Comparison of Aura Biosciences's EV-to-Revenue

For the Biotechnology subindustry, Aura Biosciences's EV-to-Revenue, along with its competitors' market caps and EV-to-Revenue data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Aura Biosciences's EV-to-Revenue Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Aura Biosciences's EV-to-Revenue distribution charts can be found below:

* The bar in red indicates where Aura Biosciences's EV-to-Revenue falls into.

Aura Biosciences EV-to-Revenue Calculation

EV-to-Revenue is a similar ratio to PS Ratio, except here Enterprise Value instead of Market Cap is used in the calculation.

Aura Biosciences's EV-to-Revenue for today is calculated as:

EV-to-Revenue	=	Enterprise Value (Today)	/	Revenue (TTM)
	=	180.589	/	0
	=

Aura Biosciences's current Enterprise Value is $180.59 Mil.
Aura Biosciences's Revenue for the trailing twelve months (TTM) ended in Mar. 2024 adds up the quarterly data reported by the company within the most recent 12 months, which was $0.00 Mil.

Aura Biosciences (NAS:AURA) EV-to-Revenue Explanation

The reason Enterprise Value is used is because Enterprise Value is more real in reflecting how much an investor pays when buying a company. For detais, go to Enterprise Value.

Aura Biosciences's PS Ratiofor today is calculated as:

PS Ratio	=	Share Price (Today)	/	Revenue per Share (TTM)
	=	7.35	/	0
	=

Aura Biosciences's share price for today is $7.35.
Aura Biosciences's Revenue per Share for the trailing twelve months (TTM) ended in Mar. 2024 adds up the quarterly data reported by the company within the most recent 12 months, which was $0.00.

Aura Biosciences EV-to-Revenue Related Terms

Thank you for viewing the detailed overview of Aura Biosciences's EV-to-Revenue provided by GuruFocus.com. Please click on the following links to see related term pages.

Aura Biosciences (Aura Biosciences) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Aura Biosciences Inc (NAS:AURA) » Definitions » EV-to-Revenue

Comparable Companies

Traded in Other Exchanges

N/A

Address

85 Bolton Street, Cambridge, MA, USA, 02140

Website

https://www.aurabiosciences.com

Aura Biosciences Inc is a clinical-stage oncology company developing a novel technology platform based on virus-like drug conjugates to target and destroy cancer cells selectively while activating the immune system to create long-lasting anti-tumor immunity.

Executives

Matrix Capital Management Company, Lp	10 percent owner	1000 WINTER STREET, C/O MATRIX CAPITAL MANAGEMENT, WALTHAM MA 02451
David Michael Johnson	director	C/O ZENTALIS PHARMACEUTICALS, LLC, 530 SEVENTH AVENUE, SUITE 2201, NEW YORK NY 10018
Julie B Feder	officer: Chief Financial Officer	C/O VERASTEM, INC., 117 KENDRICK STREET, SUITE 500, NEEDHAM MA 02494
De Los Pinos Elisabet	director, officer: Chief Executive Officer	C/O AURA BIOSCIENCES, INC., 85 BOLTON STREET, CAMBRIDGE MA 02140
Janet Jill Hopkins	officer: See Remarks	C/O AURA BIOSCIENCES, INC., 80 GUEST STREET, BOSTON MA 01235
Cadmus Rich	officer: See Remarks	C/O AURA BIOSCIENCES, INC., 85 BOLTON STREET, CAMBRIDGE MA 02140
Rosch Mark De	officer: Chief Operating Officer	C/O AURA BIOSCIENCES, INC., 85 BOLTON STREET, CAMBRIDGE MA 02140
Medicxi Ventures Management (jersey) Ltd	10 percent owner	C/O INTERTRUST FUND SERVICES (JERSEY), 44 ESPLANADE, ST. HELIER Y9 JE4 9WG
Medicxi Growth I Lp	10 percent owner	C/O ELIAN FUND SERVICES (JERSEY) LIMITED, 44 ESPLANADE, ST HELIER Y9 JE4 9WG
Giovanni Mariggi	director	C/O AURA BIOSCIENCES, INC., 85 BOLTON STREET, CAMBRIDGE MA 02140
Medicxi Growth I Gp Ltd	10 percent owner	C/O INTERTRUST FUND SERVICES (JERSEY), 44 ESPLANADE, ST. HELIER Y9 JE4 9WG
Medicxi Growth Co-invest I Lp	10 percent owner	C/O INTERTRUST FUND SERVICES (JERSEY), 44 ESPLANADE, ST. HELIER Y9 JE4 9WG
David E. Goel	10 percent owner	C/O MATRIX CAPITAL MANAGEMENT CO., LP, 1000 WINTER STREET, SUITE 4500, WALTHAM MA 02451
Karan S. Takhar	director	C/O ZENTALIS PHARMACEUTICALS,INC., 530 SEVENTH AVENUE, SUITE 2201, NEW YORK NY 10018
Antony C. Mattessich	director	C/O OCULAR THERAPEUTIX, INC., 34 CROSBY DR., SUITE 105, BEDFORD MA 01730